636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case report highlights a potential novel therapeutic avenue for ulcerative colitis, suggesting that GLP-1 RAs like semaglutide might offer benefits beyond metabolic control. The observed symptomatic remission and…
The successful completion of this trial could lead to the availability of a new semaglutide injection, potentially increasing access and offering more treatment options for Type 2 Diabetes patients. If the investigati…
This retrospective analysis holds significant potential to optimize current clinical treatment strategies for metabolic syndrome. By comparing the real-world effectiveness of established interventions like semaglutide…
This research holds significant promise for optimizing pediatric obesity treatment strategies, potentially leading to more accessible and sustainable interventions for a vulnerable population. The findings could redef…
This large-scale, pragmatic trial is crucial because it directly compares two leading therapeutic strategies for Type 2 Diabetes patients at high risk for cardiovascular and kidney complications. The findings could pr…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
This pilot study is crucial for understanding Tirzepatide's potential as a targeted therapy for MASLD, a condition with limited effective treatment options. Positive findings could pave the way for larger, more defini…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
This Phase II trial is significant because it addresses a critical unmet need for effective weight management in adult survivors of childhood Acute Lymphoblastic Leukemia (ALL), a group highly susceptible to cardiomet…
This trial is critically important because it addresses a significant gap in our understanding of how tirzepatide performs in a vulnerable and growing patient group. The findings could establish a new therapeutic opti…
If successful, this study could establish semaglutide as a safe and effective treatment option for glucose control in patients with Type 2 Diabetes and End Stage Renal Disease on dialysis. This is a particularly chall…
Understanding the safety and tolerability of BI 1820237 is a critical first step in its development as a potential new treatment for overweight and obesity. If BI 1820237 demonstrates a favorable safety profile and pr…
This trial addresses a significant gap in post-TAVR care, as current medical therapies do not adequately reduce long-term cardiovascular risks. If successful, this study could establish semaglutide as a crucial adjunc…
This research is crucial because it aims to provide a deeper understanding of how Semaglutide improves outcomes in Type 2 Diabetes beyond just weight loss and blood sugar control. By specifically targeting intramyocel…
This study addresses a critical need for practical, accessible dietary recommendations to complement GLP-1 RA therapy, potentially enhancing patient outcomes beyond just weight loss. If successful, it could provide a …
This clinical trial is profoundly significant as it explores a novel and promising therapeutic approach for ADPKD, a disease with limited treatment options and a high burden on patients. If successful, this research c…
If successful, this pilot study could pave the way for a novel pre-surgical intervention to improve outcomes for prostate cancer patients. Demonstrating the feasibility of tirzepatide-assisted weight loss could lead t…
Had it been completed, this registry would have provided an invaluable real-world dataset for understanding the long-term trajectory of obesity and metabolic diseases, offering insights into how these conditions evolv…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
This real-world study is crucial for understanding the practical effectiveness of oral semaglutide in a specific demographic, providing valuable data beyond controlled clinical trials. The findings, once published, co…
Understanding the genetic underpinnings of oral semaglutide response is crucial for advancing personalized medicine in prediabetes and obesity. This research could pave the way for personalized treatment strategies, o…
This trial holds significant promise as it explores a novel therapeutic strategy for a complex and underserved patient population. If semaglutide proves effective in reducing alcohol intake and smoking, it could offer…
The initiation of this Phase IV trial is a significant step, as it explores a novel therapeutic avenue for Idiopathic Intracranial Hypertension (IIH), a condition with limited effective treatments. Tirzepatide, known …
This trial represents a paradigm shift in Type 1 Diabetes management, potentially transforming daily life for millions by simplifying insulin delivery and reducing mental burden. If successful, tirzepatide could enabl…
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention f…
This case report holds significant clinical importance as it expands the known adverse event profile of Tirzepatide, alerting clinicians to the possibility of drug-induced liver injury. While such events are rare, rec…